Homozygous Familial Hypercholesterolemia (HoFH)
Metabolic·MeSH: Homozygous Familial Hypercholesterolemia
Prevalence
0.5 / 100K
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Evkeeza | Ultragenyx Pharmaceutical Inc. (RARE) |
Phase 3(1)
| Drug | Company |
|---|---|
| inclisiran | MEDICINES CO /DE (MDCO) |
Compare drugs
Frequently asked questions
How many drugs are in development for Homozygous Familial Hypercholesterolemia (HoFH)?
BioSniper tracks 2 drugs in development for Homozygous Familial Hypercholesterolemia (HoFH) across 2 companies.
How many clinical trials target Homozygous Familial Hypercholesterolemia (HoFH)?
There are 2 clinical trials targeting Homozygous Familial Hypercholesterolemia (HoFH) tracked by BioSniper.
What is the prevalence of Homozygous Familial Hypercholesterolemia (HoFH)?
The estimated prevalence of Homozygous Familial Hypercholesterolemia (HoFH) is approximately 0.5 per 100,000 population.
Deep-dive into Homozygous Familial Hypercholesterolemia (HoFH)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis